ErbB2 overexpression in p53-inactivated mammary epithelial cells

FEBS Letters

Volumn 580, Issue 27, 2006, Pages 6501-6508

  Yang, Jin Won ^a   Lee, Eva Y H P ^b   Kang, Keon Wook ^a  

^a Chosun University   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AP 2 ; ErbB2; Mammary epithelial cell; p53; Protein kinase A

Indexed keywords

ACTIVATOR PROTEIN 2ALPHA; ACTIVATOR PROTEIN 2BETA; ACTIVATOR PROTEIN 2GAMMA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BREAST EPITHELIUM; CONTROLLED STUDY; DNA FLANKING REGION; EXON; GENE ACTIVITY; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; UPREGULATION;

ANIMALS; EPITHELIAL CELLS; EXONS; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MICE; MICE, KNOCKOUT; MUTATION; RECEPTOR, ERBB-2; RESPONSE ELEMENTS; TRANSCRIPTION FACTOR AP-2; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 33751005270     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.10.059     Document Type: Article

References (35)

1. Mann G.B., and Borgen P.I. Breast cancer genes and the surgeon. J. Surg. Oncol. 67 (1998) 267-274
2. Giaccia A.J., and Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12 (1998) 2973-2983
3. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
4. Malkin D., Li F.P., Strong L.C., Fraumeni Jr. J.F., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 (1990) 1233-1238
5. Srivastava S., Zou Z.Q., Pirollo K., Blattner W., and Chang E.H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348 (1990) 747-749
6. Sjogren S., Inganas M., Norberg T., Lindgren A., Nordgren H., Holmberg L., and Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. 88 (1996) 173-182
7. Pavelic Z.P., Pavelic L., Lower E.E., Gapany M., Gapany S., Barker E.A., and Preisler H.D. c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res. 52 (1992) 2597-2602
8. Wright C., Nicholson S., Angus B., Sainsbury J.R., Farndon J., Cairns J., Harris A.L., and Horne C.H. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer 65 (1992) 118-121
9. Ross J.S., and Fletcher J.A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16 (1998) 413-428
10. Baselga J. Clinical trials of Herceptin(trastuzumab). Eur. J. Cancer 37 (2001) S18-S24
11. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9 (2004) 20-26
12. Jhabvala-Romero F., Evans A., Guo S., Denton M., and Clinton G.M. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2. Oncogene 22 (2003) 8178-8186
13. Lin S.C., Lee K.F., Nikitin A.Y., Hilsenbeck S.G., Cardiff R.D., Li A., Kang K.W., Frank S.A., Lee W.H., and Lee E.Y. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 64 (2004) 3525-3532
14. Menard S., Casalini P., Tomasic G., Pilotti S., Cascinelli N., Bufalino R., Perrone F., Longhi C., Rilke F., and Colnaghi M.I. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res. Treat. 55 (1999) 169-177
15. Vernimmen D., Begon D., Salvador C., Gofflot S., Grooteclaes M., and Winkler R. Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem. J. 370 (2003) 323-329
16. Deome K.B., Faulkin Jr. L.J., Bern H.A., and Blair P.B. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res. 19 (1959) 515-520
17. Schreiber E., Harshman K., Kemler I., Malipiero U., Schaffner W., and Fontana A. Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. Nucleic Acids Res. 18 (1990) 5495-5503
18. Kang K.W., Cho I.J., Lee C.H., and Kim S.G. Essential role of phosphatidylinositol 3-kinase-dependent CCAAT/enhancer binding protein beta activation in the induction of glutathione S-transferase by oltipraz. J. Natl. Cancer Inst. 95 (2003) 53-66
19. Akiyama T., Matsuda S., Namba Y., Saito T., Toyoshima K., and Yamamoto T. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol. Cell. Biol. 11 (1991) 833-842
20. Segatto O., Lonardo F., Pierce J.H., Bottaro D.P., and Di Fiore P.P. The role of autophosphorylation in modulation of erbB-2 transforming function. New Biol. 2 (1990) 187-195
21. Bosher J.M., Totty N.F., Hsuan J.J., Williams T., and Hurst H.C. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 13 (1996) 1701-1707
22. Pellikainen J., Naukkarinen A., Ropponen K., Rummukainen J., Kataja V., Kellokoski J., Eskelinen M., and Kosma V.M. Expression of HER2 and its association with AP-2 in breast cancer. Eur. J. Cancer 40 (2004) 1485-1495
23. Treisman R. Regulation of transcription by MAP kinase cascades. Curr. Opin. Cell Biol. 8 (1996) 205-215
24. Guccione M., Silbiger S., Lei J., and Neugarten J. Estradiol upregulates mesangial cell MMP-2 activity via the transcription factor AP-2. Am. J. Physiol. Renal Physiol. 282 (2002) F164-F169
25. Tuli R., Seghatoleslami M.R., Tuli S., Howard M.S., Danielson K.G., and Tuan R.S. p38 MAP kinase regulation of AP-2 binding in TGF-beta1-stimulated chondrogenesis of human trabecular bone-derived cells. Ann. NY Acad. Sci. 961 (2002) 172-177
26. Garcia M.A., Campillos M., Marina A., Valdivieso F., and Vazquez J. Transcription factor AP-2 activity is modulated by protein kinase A-mediated phosphorylation. FEBS Lett. 444 (1999) 27-31
27. Meaney M.J., Diorio J., Francis D., Weaver S., Yau J., Chapman K., and Seckl J.R. Postnatal handling increases the expression of cAMP-inducible transcription factors in the rat hippocampus: the effects of thyroid hormones and serotonin. J. Neurosci. 20 (2000) 3926-3935
28. Levine A.J., Momand J., and Finlay C.A. The p53 tumour suppressor gene. Nature 351 (1991) 453-456
29. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002) 594-604
30. Nagahata T., Kosaka N., and Shimizu M. Molecular diagnosis for breast cancer. Jap. Med. Assoc. J. 45 (2002) 265-270
31. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
32. Eissa S., Khalifa A., el-Gharib A., Salah N., and Mohamed M.K. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer. Anticancer Res. 17 (1997) 1417-1423
33. Barbareschi M., Leonardi E., Mauri F.A., Serio G., and Dalla Palma P. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am. J. Clin. Pathol. 98 (1992) 408-418
34. Perissi V., Menini N., Cottone E., Capello D., Sacco M., Montaldo F., and De Bortoli M. AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen. Oncogene 19 (2000) 280-288
35. Xing X., Wang S.C., Xia W., Zou Y., Shao R., Kwong K.Y., Yu Z., Zhang S., Miller S., Huang L., and Hung M.C. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat. Med. 6 (2000) 189-195